Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors

#2168

Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.

Aim(s): We conducted a two-cohort phase II study to evaluate efficacy of cabozantinib in patients (pts) with advanced carcinoid (CARC) or pancreatic NET (pNET) (NCT01466036).

Materials and methods: Pts with progressive, well-differentiated CARC or pNET were treated with cabozantinib 60 mg daily. Pts were restaged q2 cycles for the first 6 cycles, then q3 cycles. The primary endpoint was response rate (RECIST 1.1).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan J, Faris J, Murphy J, Blaszkowsky L, McCleary N,

Keywords: cabozantinib, pancreatic neuroendocrine tumor, carcinoid, phase II,